Related Experiment Video
Updated: Jun 13, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
[Paraneoplastic opsoclonus-myoclonus syndrome--a review]
Hideyuki Matsumoto1, Yoshikazu Ugawa
1Department of Neurology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Abstract:
The aim of this article is to review the paraneoplastic opsoclonus-myoclonus syndrome (POMS). Opsoclonus is characterized by involuntary, arrhythmic, chaotic, multi-directional saccades with horizontal, vertical and torsional components, and it is commonly accompanied by cerebellar ataxia and myoclonic jerks in the trunk and limbs. Parainfectious brainstem encephalitis, toxic-metabolic disturbances and others condition should be considered as potential causes of these symptoms. In adults, POMS is most commonly associated with small-cell lung cancer, breast cancer, and ovarian cancer. In children, a neuroblastoma is detected in approximately 50% of cases. Many autoantibodies have been detected in patients with POMS: this finding suggests the involvement of a humoral immune mechanism. However, most patients are seronegative for these autoantibodies. This implies that a cell-mediated immune mechanism may also be involved in the pathogenesis of opsoclonus. Although the exact pathophysiology mechanism of opsoclonus remains unclear, recent reports suggest that disinhibition of the fastigial nucleus of the cerebellum is involved. In children, the immunotherapy with corticosteroids, intravenous immunoglobulin, adrenocorticotropic hormone, plasma exchange, cyclophosphamide, or rituximab is used. Although opsoclonus is often responsive to therapy, the high incidence of sequelae related to motor function, speech, behavior, and sleep is an important problem. In adults, POMS is less responsive to immunotherapy and improves only with tumor resection. In order to develop novel and effective therapeutic strategies, further studies on the immunopathogenesis and pathophysiology of POMS are required.
Insights
Paraneoplastic opsoclonus-myoclonus syndrome (POMS) involves chaotic eye movements and myoclonus, often linked to cancers. Research is needed for better POMS treatments, especially given its neurological sequelae.
Area of Science:
- Neurology
- Immunology
- Oncology
Context:
- Paraneoplastic opsoclonus-myoclonus syndrome (POMS) presents with opsoclonus, ataxia, and myoclonus.
- POMS is associated with specific cancers (lung, breast, ovarian in adults; neuroblastoma in children).
- Differential diagnoses include parainfectious encephalitis and toxic-metabolic conditions.
Purpose:
- To review the clinical features, potential causes, and immunopathogenesis of POMS.
- To discuss current therapeutic strategies and their limitations in POMS management.
- To highlight the need for further research into POMS pathophysiology and novel treatments.
Summary:
- POMS is characterized by involuntary saccadic eye movements and myoclonus, frequently linked to underlying malignancies.
- Autoantibodies suggest humoral immunity, but seronegativity implies a role for cell-mediated immunity in POMS pathogenesis.
- Cerebellar fastigial nucleus disinhibition is a proposed mechanism, though POMS pathophysiology requires further elucidation.
Impact:
- Understanding POMS immunopathogenesis is crucial for developing targeted therapies.
- Effective POMS treatment, especially in children, requires addressing neurological sequelae.
- Improved therapeutic strategies are needed for POMS, particularly in adults where tumor resection is key.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cushing Syndrome II: Pathophysiology
Cushing Syndrome I: Introduction
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

